Phase 2 Study of VGT-309 in Lung Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-24

Study Completion Date

2023-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Phase 2 open label study to evaluate safety and efficacy of VGT-309 to identify cancer in up to 40 subjects undergoing lung cancer surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SLN Detection With Tc-MSA-ICG in Lung Cancer Patients

NCT05039905

Lung Cancer

UNKNOWN EARLY_PHASE1

Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.

NCT03220230

Lung Neoplasms

COMPLETED

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

NCT02715102

Cancer of the Lung Lung Cancer Lung Neoplasms +3 more

TERMINATED

Detection of Genetic Markers of Lung Cancer

NCT00280202

Lung Cancer

RECRUITING

Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer

NCT00603057

Non-Small Cell Lung Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Phase 2, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer in subjects undergoing lung cancer surgery. A total of 40 subjects will be enrolled to ensure at least 38 evaluable subjects with the option to expand enrollment by protocol amendment if deemed necessary to meet primary and/or secondary objectives.

Following agreement with and signing of the informed consent, subjects will undergo screening measurements for the study. Assessments include the following, unless they have been done within 4 weeks prior to the anticipated dosing:

1. Medical, surgical and medication history.
2. Complete physical exam, including vital signs and weight.
3. Standard pre-operative chemistry, hematology, coagulation and urinalysis clinical laboratory studies.
4. 12-lead ECG.
5. Serum pregnancy test for females of child-bearing potential.

Following clearance of all enrollment criteria, each subject will receive an IV administration of 0.32 mg/kg VGT-309 at 12-36 hours prior to surgery (refer to section VGT-309 Dosing, below). Upon dosing, subjects will be observed for up to 2 hours and asked about possible treatment emergent adverse events.

Subjects will undergo surgical resection as planned and within the time specified following VGT-309 dosing. Measurements of efficacy will be taken during surgery and during the pathological examination of all surgical specimens.

Following surgery, subjects will be monitored for safety during their hospitalization. After discharge from the hospital, and approximately 14 days post-surgery, the subjects will be contacted by telephone to assess their well-being. Between 19 to 39 days post-surgery, subjects will either return to the clinic or participate in a telehealth visit for final safety assessments. If there are no adverse events requiring further follow up, subjects will then be released from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

All subjects to be dosed at the same dose level. This is open label and no randomization is required.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.32mg/kg VGT-309

Single arm in an open label study

Group Type EXPERIMENTAL

VGT-309

Intervention Type DRUG

VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VGT-309

VGT-309 is an tumor-targeted, activatable fluorescent imaging agent which will be used with near infrared imaging during surgery to identify tumor.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be willing and able to sign the informed consent and comply with study procedures.
2. Be between the ages of 18 and 85, inclusive.
3. Be male or female and meet the following conditions:

1. Female participants must be of non-childbearing potential, or,
2. If of childbearing potential be non-pregnant or non-lactating and agree to use highly effective contraception from screening through Day 30.
3. Male participants, if not surgically sterilized, and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 30 days post-dose and agree not to donate semen during this waiting period.
4. Highly effective contraception involves the use of a condom for the male, plus one of the following for the female:

* Oral, injectable, implantable, intravaginal, or transdermal hormonal contraceptives, or
* Intrauterine device or intrauterine hormone-releasing system
* NOTE: Participants who abstain from heterosexual intercourse as their usual and preferred lifestyle, will not be required to use contraception as described above.

They are required to maintain abstinence from screening through Day 30.
4. Have a lung nodule or mass that might be considered primary lung cancer or lung metastases, whether or not it is biopsy-proven.
5. Be scheduled to undergo standard of care surgical resection for a lung nodule or mass with diagnostic and/or curative intent and meet all pre-operative surgical and anesthesia acceptance criteria.
6. Have acceptable kidney and liver functions at study entry as evidenced by:

1. Alanine Aminotransferase/Aspartate Aminotransferase (ALT/AST) \< 1.5 times the upper limit of normal
2. Serum creatinine \< 1.5 times the upper limit of normal
7. Have an Eastern Cooperative Oncology Group (ECOG) score of 0-2.
8. Meet all standard surgical and general anesthesia requirements.
9. Have not participated in a clinical trial within the last 30 days.

Exclusion Criteria

1. They are not a candidate for standard of care surgery based on opinion of the surgeon, anesthesiologist, or other consulting physician.
2. They have a known allergy or reaction to indocyanine green (ICG), other radiographic contrast agent, or any component of VGT-309.
3. Have congenital long QT syndrome or QTcF \> 450ms (males) or \>470ms (females) by history or at Screening ECG.
4. They are prisoners, institutionalized individuals, or are unable to consent for themselves.
5. Have any other co-morbidity or habit that the Investigator believes will interfere with their ability to comply with and complete the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No